Suppr超能文献

金属硫蛋白抑制小鼠心脏的缺血再灌注损伤。

Metallothionein inhibits ischemia-reperfusion injury in mouse heart.

作者信息

Kang Y J, Li G, Saari J T

机构信息

Departments of Medicine, and Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA.

出版信息

Am J Physiol. 1999 Mar;276(3):H993-7. doi: 10.1152/ajpheart.1999.276.3.H993.

Abstract

Oxidative stress is believed to play a major role in ischemia-reperfusion injury to the heart. Metallothionein (MT), a potential free radical scavenger, may function in cardiac protection against ischemia-reperfusion damage. To test this hypothesis, a specific cardiac MT-overexpressing transgenic mouse model was used. The hearts isolated from these animals were subjected to 50 min of warm (37 degrees C) zero-flow ischemia followed by 60- or 90-min reflow. Compared with the nontransgenic controls, the transgenic mouse hearts with MT concentrations approximately 10-fold higher than normal showed significantly improved recovery of contractile force postischemia (69.2 +/- 4.2 vs. 26.0 +/- 6.0% at the end of 60-min reperfusion, P < 0.01). Efflux of creatine kinase from these transgenic hearts was reduced by more than 50% (P < 0.01). In addition, the zone of infarction induced by ischemia-reperfusion at the end of 90-min reperfusion was suppressed by approximately 40% (P < 0.01) in the transgenic hearts. The results strongly indicate that MT provides protection against ischemia-reperfusion-induced heart injury.

摘要

氧化应激被认为在心脏缺血再灌注损伤中起主要作用。金属硫蛋白(MT)作为一种潜在的自由基清除剂,可能在心脏保护中发挥作用,抵抗缺血再灌注损伤。为了验证这一假设,使用了一种特定的心脏MT过表达转基因小鼠模型。从这些动物身上分离出的心脏先经历50分钟的温性(37摄氏度)零流量缺血,随后进行60或90分钟的再灌注。与非转基因对照组相比,MT浓度比正常水平高约10倍的转基因小鼠心脏在缺血后收缩力的恢复方面有显著改善(60分钟再灌注结束时为69.2±4.2%对26.0±6.0%,P<0.01)。这些转基因心脏中肌酸激酶的流出减少了50%以上(P<0.01)。此外,在90分钟再灌注结束时,转基因心脏中缺血再灌注诱导的梗死区域被抑制了约40%(P<0.01)。结果有力地表明,MT对缺血再灌注诱导的心脏损伤具有保护作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验